The American Journal of Medicine
Volume 123, Issue 9 , Pages 777-784 , September 2010

Practical Considerations for Planning a Therapeutic Apheresis Procedure

  • Suresh G. Shelat, MD, PhD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Suresh G. Shelat, MD, PhD, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104

References 

  1. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories—introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher. 2007;22:96–105
  2. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2007;22:106–175
  3. Shaz BH, Linenberger ML, Bandarenko N, et al. Category IV indications for therapeutic apheresis: ASFA fourth special issue. J Clin Apher. 2007;22:176–180
  4. In:  McLeod B editors. Apheresis, Principles and Practice. Bethesda, MD: AABB Press; 2003;
  5. Brecher M. AABB Technical Manual. 15th edn.. Bethesda, MD: AABB Press; 2005;
  6. Kim HC. Therapeutic pediatric apheresis. J Clin Apher. 2000;15(1-2):129–157
  7. Jones H, Bandarenko N. Management of the therapeutic apheresis patient. In:  McLeod B editors. Apheresis, Principles and Practice. 2nd edn.. Bethesda, MD: AABB Press; 2003;p. 253–273
  8. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998;38:938–943
  9. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher. 1994;9:1–5
  10. Huestis DW. Risks and safety practices in hemapheresis procedures. Arch Pathol Lab Med. 1989;113:273–278
  11. McLeod BC, Sniecinski I, Ciavarella D, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999;39(3):282–288
  12. McLeod BC. Therapeutic Apheresis: A Physician's Handbook. Bethesda, MD: AABB Press; 2005;
  13. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients (Excess length of stay, extra costs, and attributable mortality). JAMA. 1994;271:1598–1601
  14. Raad II, Luna M, Khalil SA, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA. 1994;271:1014–1016
  15. Crookston KP, Simon TL. Physiology of apheresis. In:  McLeod BC,  Price TH,  Weinstein R editor. Apheresis: Principles and Practice. 2nd edn.. Bethesda MD: AABB Press; 2003;p. 71–90
  16. Davis TM, Singh B, Choo KE, et al. Dynamic assessment of the electrocardiographic QT interval during citrate infusion in healthy volunteers. Br Heart J. 1995;73:523–526
  17. RuDusky BM. ECG abnormalities associated with hypocalcemia. Chest. 2001;119:668–669
  18. Weinstein R. Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. J Clin Apher. 2001;16:210–211
  19. Dodd RY. Current estimates of transfusion safety worldwide. Dev Biol (Basel). 2005;120:3–10
  20. Dodd RY, Notari EPt, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–979
  21. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev. 2001;15:69–83
  22. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17:120–162
  23. Kellogg RM, Hester JP. Kinetics modeling of plasma exchange: intra- and post-plasma exchange. J Clin Apher. 1988;4:183–187
  24. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223–1229
  25. Introduction to therapeutic apheresis: principles, physiology, and patient management. In:  McLeod B editors. Therapeutic Apheresis: A Physician's Handbook. Bethesda, MD: AABB Press; 2005;p. 1–32
  26. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA. 2007;297:2264–2277
  27. Red cell exchange. In:  McLeod B editors. Therapeutic Apheresis: A Physician's Handbook. Bethesda, MD: AABB Press; 2005;p. 115–134
  28. Roseff S, Gotschall G. Pediatric Transfusion: A Physician's Handbook. 3rd edn.. Bethesda, MD: AABB Press; 2009;
  29. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. In:  Berkman EM,  Ulmas J editor. Therapeutic Hemapheresis: A Technical Workshop. Washington DC: American Association of Blood Banks; 1980;p. 13–52
  30. Ibrahim RB, Liu C, Cronin SM, et al. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy. 2007;27:1529–1549
  31. Fauvelle F, Petitjean O, Tod M, Guillevin L. Clinical pharmacokinetics during plasma exchange. Therapie. 2000;55:269–275
  32. Kintzel PE, Eastlund T, Calis KA. Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher. 2003;18:194–205
  33. Shaz BH, Winters JL, Bandarenko N, Szczepiorkowski ZM. How we approach an apheresis request for a Category III, Category IV, or noncategorized indication. Transfusion. 2007;47:1963–1971
  34. McLeod BC. An approach to evidence-based therapeutic apheresis. J Clin Apher. 2002;17:124–132
  35. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994;34:891–894
  36. Perseghin P, Capra M, Baldini V, Sciorelli G. Bradykinin production during donor plasmapheresis procedures. Vox Sang. 2001;81:24–28
  37. Siami GA, Siami FS, Morrow JD, Stone WJ. Cryofiltration apheresis and plasma fractionation causing anaphylactoid reactions in patients receiving angiotensin converting enzyme inhibitors. Ther Apher. 1997;1:325–329
  38. Rogers R, Cooling L. Therapeutic apheresis in pediatric patients. In:  McLeod B editors. Apheresis: Principles and Practice. 2nd edn.. Bethesda, MD: AABB Press; 2005;p. 477

 Funding: None.

 Conflict of Interest: There are no conflicts of interest to report.

 Authorship: The author accepts sole responsibility for the data and for manuscript preparation.

PII: S0002-9343(10)00231-7

doi: 10.1016/j.amjmed.2010.01.022

The American Journal of Medicine
Volume 123, Issue 9 , Pages 777-784 , September 2010

Article Tools